Next Article in Journal
Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
Previous Article in Journal
In-Clinic versus Hybrid Cancer Rehabilitation Service Delivery during the COVID-19 Pandemic: An Outcome Comparison Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 30
Issue 10
10.3390/curroncol30100645
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience

by
Yue (Jennifer) Du
1,2,
Rui Fu
2,
Justin T. Levinsky
2,
Pabiththa Kamalraj
2,
Kelvin K. W. Chan
3,
Ambica Parmar
3,
Antoine Eskander
2 and
Martin Smoragiewicz
3,*
1
Temerty School of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada
2
Department of Otolaryngology—Head and Neck Surgery, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
3
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2023, 30(10), 8928-8935; https://doi.org/10.3390/curroncol30100645
Submission received: 26 August 2023 / Revised: 19 September 2023 / Accepted: 27 September 2023 / Published: 29 September 2023
Browse Figures
Review Reports Versions Notes

Abstract

Nivolumab, a PD-1 checkpoint inhibitor, was approved in Canada in 2017 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the phase 3 trial CHECKMATE-141. We aimed to examine the demographics and efficacy of nivolumab in a Canadian, real-world setting. A retrospective chart review was performed on patients who received nivolumab for R/M HNSCC from 2017 to 2020 at a high-volume cancer centre. Data were abstracted from 34 patients, based on physician notes and imaging reports. The median patient age at nivolumab initiation was 61, 24% were female, and 62% were current or former smokers. Prior to nivolumab, 44% of patients underwent surgery, 97% radiation, and 100% chemotherapy. Most (97%) therapies were for primary disease. Overall survival at 6 and 12 months following drug initiation was 38% and 23%, respectively. Progression-free survival at 6 and 12 months was 33% and 22%, respectively. Eighteen percent of patients experienced an immune-related adverse event, the most common of which was pneumonitis (3/8) and endocrine events (3/8). Seven out of eight of the immune adverse events were grade 1–2; 1/8 was grade 3. Nivolumab appears to have decreased survival rates in our single-centre Canadian population compared to CHECKMATE-141 and presented a manageable adverse event profile for R/M HNSCC.
Keywords: nivolumab; head and neck; squamous cell carcinoma; cancer; chemotherapy; PD-1 checkpoint inhibitor nivolumab; head and neck; squamous cell carcinoma; cancer; chemotherapy; PD-1 checkpoint inhibitor
Graphical Abstract

Share and Cite

MDPI and ACS Style

Du, Y.; Fu, R.; Levinsky, J.T.; Kamalraj, P.; Chan, K.K.W.; Parmar, A.; Eskander, A.; Smoragiewicz, M. Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience. Curr. Oncol. 2023, 30, 8928-8935. https://doi.org/10.3390/curroncol30100645

AMA Style

Du Y, Fu R, Levinsky JT, Kamalraj P, Chan KKW, Parmar A, Eskander A, Smoragiewicz M. Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience. Current Oncology. 2023; 30(10):8928-8935. https://doi.org/10.3390/curroncol30100645

Chicago/Turabian Style

Du, Yue (Jennifer), Rui Fu, Justin T. Levinsky, Pabiththa Kamalraj, Kelvin K. W. Chan, Ambica Parmar, Antoine Eskander, and Martin Smoragiewicz. 2023. "Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience" Current Oncology 30, no. 10: 8928-8935. https://doi.org/10.3390/curroncol30100645

APA Style

Du, Y., Fu, R., Levinsky, J. T., Kamalraj, P., Chan, K. K. W., Parmar, A., Eskander, A., & Smoragiewicz, M. (2023). Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre’s Real-World Experience. Current Oncology, 30(10), 8928-8935. https://doi.org/10.3390/curroncol30100645

Article Metrics

Back to TopTop